The immune checkpoints’ expression has a role in immune escape via inhibiting the T-cell response, and immune checkpoint inhibitors have been widely used for melanoma, especially anti-CTLA4 and anti-PD-1 antibodies (Carlino et al., 2021). Here, CTLA4 is linked to melanoma.